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ABSTRACT
Purpose Polyamidoamine (PAMAM) dendrimers are a
promising class of nanocarrier with applications in both small
and large molecule drug delivery. Here we report a compre-
hensive evaluation of the uptake and transport pathways that
contribute to the lung disposition of dendrimers.
Methods Anionic PAMAM dendrimers and control dextran
probes were applied to an isolated perfused rat lung (IPRL)
model and lung epithelial monolayers. Endocytosis pathways
were examined in primary alveolar epithelial cultures by con-
focal microscopy. Molecular interactions of dendrimers with
protein and lipid lung fluid components were studied using
small angle neutron scattering (SANS).
Results Dendrimers were absorbed across the intact
lung via a passive, size-dependent transport pathway at
rates slower than dextrans of similar molecular sizes. SANS
investigations of concentration-dependent PAMAM transport
in the IPRL confirmed no aggregation of PAMAMs with
either albumin or dipalmitoylphosphatidylcholine lung
lining fluid components. Distinct endocytic compart-
ments were identified within primary alveolar epithelial
cells and their functionality in the rapid uptake of
fluorescent dendrimers and model macromolecular
probes was confirmed by co-localisation studies.
Conclusions PAMAM dendrimers display favourable lung
biocompatibility but modest lung to blood absorption kinetics.
These data support the investigation of dendrimer-based car-
riers for controlled-release drug delivery to the deep lung.
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ABBREVIATIONS
BSA Bovine serum albumin
DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
IPRL Isolated perfused rat lung
MRI Magnetic resonance imaging
PAMAM Polyamidoamine
INTRODUCTION
Dendrimers represent an important uniform and nanosized
polymer architecture for biomedical and clinical applications
and display a variety of synthetic approaches, chemistries, and
an ability to carry cargo either by encapsulation, complexa-
tion or as pendant groups on the polymer surface. Dendrimers
retain promise as nanosized drug carriers displaying a narrow
polydispersity and an ease of control in the modification of
surface functional groups. The first full family of dendrimer
molecules, spanning a number of growth generations were the
poly(amidoamine) (PAMAM) dendrimers synthesised by the
divergent approach with the iterative addition of methyl ac-
rylate and ethylenediamine to a polymer core and modified
with hydroxyl (neutral), amine (positive) or carboxyl (negative)
surface functionalities (Scheme 1).
The polyamidoamine (PAMAM) class of dendrimers have
been the most widely studied as carriers for low molecular
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weight drugs, for MRI contrast agents, and as carriers of
biomacromolecules including vaccines, peptides, antibodies
and DNA. A number of groups have used cationic PAMAM
dendrimers to enhance drug delivery across cell membranes,
including avoidance of efflux transporters (1), or for example
enhancing cytoplasmic delivery of nucleic acid therapeutics (2)
or vaccines (3). However, cell membrane disruption and com-
promise of tight junction integrity is a significant concern for
the exploitation of cationic dendrimers, although approaches
have been developed to mitigate the biocompatibility issues
associated with the use of these platforms (4).
The dendrimer-enhanced delivery of drugs with low oral
bioavailability has been of particular interest with many studies
(5) reporting dendrimer permeation of cultured intestinal
epithelial cell monolayers, although fewer investigations of
transport in the fully intact ex vivo or in vivo tissue have been
evidenced. Using an everted gut sac model Wiwatanapatapee
et al. (6) reported the effect of dendrimer generation and surface
functionality (anionic and cationic) upon the association of
PAMAM dendrimers with intestinal tissue and upon dendri-
mer mucosal to serosal transport. In an in-vivo rat model
Florence and co-workers (7) administered by oral solution
gavage a poly(lysine)15 dendrimer bearing at the surface cova-
lently linked C12 alkyl chains and studied the subsequent in-
testinal and whole body tissue accumulation.
In contrast to the oral route, the pulmonary administration
of dendrimers has received relatively little consideration and
may offer a number of distinct benefits for the localised airway
delivery of drugs that require controlled luminal release, but
also for the transmucosal or systemic delivery of dendrimer
bearing therapeutic cargo. Indeed many reports have
highlighted the favourable lung bioavailability of biologics in
the absence of absorption enhancers (reviewed in (8,9)).
Systematic investigations of lung permeability to nano-sized
polymers such as PAMAM dendrimers are limited, and par-
ticularly those conducted in a model that retains a fully intact
pulmonary architecture.
In this study, we utilised an isolated perfused rat lung (IPRL)
model to quantify the rate and extent of absorption from the
deep lung of a series of anionic PAMAM dendrimers spanning
a molecular weight range 3 to 53 kDa. Following airway
administration of the dendrimers in the IPRL model, we
observed size-dependent pulmonary transport kinetics for
three generations (G1.5, G3.5 and G5.5) of anionic PAMAM
Scheme 1 (a) Structure of
exemplar anionic PAMAM
generation 1.5. Iterative branching
of each generation is highlighted by
concentric circles. (b) Molecular
mass (Mw) and the number of
surface functional groups for the
PAMAM generations tested here.
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dendrimers. In the IPRL, the rate of PAMAM transport from
the lung lumen to the pulmonary circulation tended to be less
than the dextran probes of comparable molecular dimensions.
Further, with respect toG3.5 andG5.5 dendrimers we observed
dose-dependent absorption from the airways of the IPRL. Small
angle neutron scattering (SANS) studies indicated that this dose-
dependency was not attributable to interaction of G3.5 or G5.5
with either of the two principal components of lung lining fluid,
i.e. albumin and the zwitterionic surfactant, 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC). Using lung epithelial cell
culture models, we also examined the comparative in-vitro per-
meability of the dendrimers as well as their endocytic uptake
and intracellular accumulation within distinct vesicular com-
partments of lung epithelia. In summary, these data indicate
that PAMAM dendrimers offer a promising polymeric delivery
platform that could be used to deliver drug cargo either into, or
indeed, across the deep lung respiratory epithelium.
MATERIALS & METHODS
Materials
The following were obtained from Sigma-Aldrich (Poole,
UK):anionic PAMAM dendrimer generations (PAMAM) 1.5,
PAMAM 3.5 and PAMAM 5.5 (nominal MWs 3KDa,
13KDa, 53KDa, respectively), N-hydroxysulfosuccinimide
(sulfo-NHS), 1-ethyl-3(3-dimethylaminopropyl) carbodiimide
hydrochloride (EDC), sodium fluorescein (F-Na) and bovine
serum albumin (>98% purity) and FITC-dextans (FDx, where
x represents the nominal molecular weight in kDa). All tissue
culture plastics were from Corning Costar (Hemel Hempstead,
UK). Anti-caveolin-1 and anti-EEA-1 antibodies were from
BD Biosciences (UK). Oregon Green 488 (OG) cadaverine,
fluorescently labelled probes (10 kDa dextran, bovine serum
albumin and cholera toxin B subunit) were all from
Invitrogen (Paisley, UK). All other chemicals and reagents were
of the highest possible quality from Fisher Scientific
(Loughborough, UK) or Sigma (Poole, UK). Hydrogenous
and deuterated 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
(DPPC) were from Avanti Polar Lipids Inc. (USA). Sources of
other exceptional items are mentioned in the text.
Fluorescent Labelling of PAMAM Dendrimers
To allow quantification of pulmonary transport and cell up-
take, dendrimers were labelled with Oregon Green 488 ca-
daverine (OG) using carbodiimide-mediated coupling chem-
istry and purified and characterised as previously described
(10). The extent of dendrimer-fluorophore labelling was
minimised to reduce interference with the surface properties.
Substitution ranged from 1:1.04 to 1:1.31 molar ratio (den-
drimer: fluorophore).
Primary Alveolar Epithelial Cell Cultures
Isolation and primary culture of type II rat alveolar epithelial
(ATII) cells to an alveolar epithelial type I cell (ATI-like) phe-
notype was undertaken according to procedures previously
reported (11). All animal experiments and the protocols de-
scribed below adhered to the Animal (Scientific Procedures)
Act 1986 (United Kingdom).
Permeability of Polarised Calu-3 Monolayers
to PAMAM Dendrimers and FITC-Dextrans
Calu-3 monolayers were grown on Transwell® Clear inserts
(0.4 μm pore size) for 10–14 days until the transepithelial
electrical resistance (TEER) values were >500Ω.cm2 as mea-
sured using ENDohm chambers and an EVOM epithelial
voltohmeter (Word Precision instruments, Sarosota, USA).
Culture media was aspirated, apical and basal chambers were
gently washed with warm PBS and bathing fluid replaced with
DMEM–F12 (without phenol red). After equilibration
(30 min, 37°C) 0.2 mL of dose solution (8 μM or 40 μM
PAMAM-OG in serum-free media) was applied to the donor
chamber. Cumulative PAMAM-OG transport across the
monolayers (37°C, upon an orbital shaker) was measured at
pre-determined intervals by sampling 0.2 mL from the basal
chamber and replacement with an equal volume of warm
media. In addition, transport studies were performed using a
molecular weight range of FITC-dextrans and F-Na (40 μM
donor concentration) as reference solutes. The cumulative
transport of each probe was calculated and an apparent per-
meability coefficient (Papp) (cm.s
−1) determined according to:
Papp ¼ dMdt ⋅
1
A:C0
ð1Þ
where: δM/δt is the rate of probe accumulation in the basal
chamber (calculated from the initial linear portion of the
transport curve); A denotes the 0.332 cm2 surface area of
the Transwell® inserts and C0 denotes the initial concentra-
tion of probe in the donor chamber.
Imaging of Endocytic Compartments in Primary Rat
Alveolar Epithelial and Calu-3 Cells
Coverslip mounted ATI-like cells were fixed with 3%
paraformaldehyde, quenched with 50 mM NH4Cl, then
permeabilised with 0.2% Triton X-100 in PBS.
Coverslips were incubated with primary antibodies against
Caveolin-1 (Cav-1), early-endosomal antigen-1 (EEA-1) dilut-
ed in blocking buffer (dilutions: Cav-1 1:200; EEA-1 1:200 for
30 min). Lysosomes were labelled by pulse-chase labelling (2 h
pulse-3 h chase) with 0.25 mg/mL tetramethylrhodamine-
dextran in serum-free medium.
Lung Delivery of PAMAM Dendrimers
PAMAM-OG uptake was studied in ATI-like cells seeded
onto glass bottomed 35 mm culture dishes (MatTek
Corporation, Ashland, USA). ATII primary cell were cultured
over 6–8 days to achieve an ATI-like phenotype. To assess
probe uptake, cells were washed with warm PBS (x3), before
addition of PAMAM-OG conjugate (50 nM in DMEM with-
out phenol red, containing 15 mM HEPES) for pre-
determined times. Co-internalisation of PAMAM-OG conju-
gates with 100 μg/mL tetramethylrhodamine-BSA (30 min)
or dextran in ATI-like cells was used to co-localise to albumin
positive endosomes and lysosomal compartments, respective-
ly. Following incubation at 37°C, cells were washed with pre-
warmed PBS then immediately imaged by fluorescent imag-
ing on a Leica DMIRB fluorescent microscope equipped with
a 40x objective and attached to a Digital CCD Retiga 1300
camera, processed using Improvision software. Images were
cropped and annotated for publication using Photoshop CS2
(Adobe Systems Inc.).
Pulmonary Translocation of Solutes in an Ex-Vivo IPRL
Model
An IPRL preparation using a pMDI intra-tracheal solution
instillation technique was used as previously described (12). A
critical appraisal of the IPRL model as well as a schematic
representation has previously been published (13). PAMAM-
OG conjugates were administered to the IPRL in 0.1 mL
20 mM PBS, pH 7.4. Serial aliquots were sampled from the
recirculating perfusate at pre-determined times and centri-
fuged (13,000 g, 10 min, 4°C) to remove trace blood cells
and the supernatant stored at −80°C prior to quantification
by microplate fluorescence spectroscopy (λex 485 nm λem
520 nm; FLUOstar, BMG, Aylesbury, UK). A calibration
curve for each PAMAM-OG conjugate was prepared in con-
trol perfusate that had recycled through the lung for 60 min.
Cumulative transfer of dendrimer into the perfusate was cal-
culated by multiplying the cumulative concentration by the
total perfusate volume (~75 mL). The wet:dry ratio of lung
tissue was calculated by comparison of the tissue weight im-
mediately after the IPRL experiment (wet weight) and the
tissue weight after lyophilisation for 72 h (dry weight).
Control experiments involved instillation of PBS dose solution
followed by perfusion and ventilation for 60 min.
Lipid Vesicle Preparation
Small unilamellar vesicles comprising h-DPPC or d-DPPC
were prepared using the freeze/thaw extrusion method.
DPPC was dissolved in chloroform (10mg /mL) in a round
bottom flask then solvent was removed by rotary evaporation
to yield a phospholipid film. Residual solvent was removed
under high vacuum for 1 h. The film was rehydrated in
2 mL deuterated phosphate-buffered saline pH 6.5 (Sigma-
Aldrich, Poole, UK) then incubated at 50°C for 1 h. The
hydrated film was then subjected to five freeze/thaw cycles
which involved freezing for 5 min in liquid nitrogen followed
by thawing for 5 min in water at 50°C and then vortex mixing
for 5 min. Finally, the lipid mixture was extruded under high
pressure, firstly through a 200 nm polycarbonate membrane
(10 times) and secondly through a 100 nm polycarbonate
membrane (20 times) using The Extruder (Lipex
Biomembranes Inc., Vancouver, Canada) maintained at
50°C.
SANS Studies on PAMAM Dendrimer in Lung Fluid
Models
SANS experiments were performed on the D11 diffractome-
ter based at the steady-state reactor source at the Institut
Laue-Langevin (ILL) in Grenoble, France. A Q range of
0.01 Å−1 to 0.5 Å−1 was selected by choosing several instru-
ment settings (sample-to-detector distances, collimation) with
a constant neutron wavelength (λ) of 8 Å, where:
Q ¼ 4π=λð Þsin ϑ=2ð ÞQ ¼ 4π
λ
 
sin
θ
2
 
: ð2Þ
Samples were contained in 1 mm pathlength, UV-
spectrophotometer grade, quartz cuvettes (Hellma) and thermo-
statically controlled at 25 ± 0.5°C can be achieved.
Experimental measuring times were dependent on the sample-
detector distance, but approximately 40–60 min overall.
All scattering data were normalised for the sample trans-
mission and the incident wavelength distribution, corrected
for instrumental and sample backgrounds using a quartz cell
filled with D2O, and corrected for the linearity and efficiency
of the detector response using the instrument specific software
package. The data were put onto an absolute scale using a
well-characterized partially deuterated polystyrene blend
standard sample.
Previous SANS studies on PAMAMs have shown that they
form spherical structures (14). Here, the data were fitted to a
model that describes the scatterer as a solid, spherical object. In
this representation, the scattered intensity, I(Q), is expressed as:
I Qð Þ ¼ scalev : 3V Δρð Þ:
sin qrð Þ−qr cos qrð Þ
qrð Þ3
" #2
þ Binc ð3Þ
Where scale is a volume fraction, V is the volume of the
scatterer, r is the radius of the sphere, Δρ is the difference
between the scattering length density of the scatterer and the
solvent, and Binc is the incoherent background scattering. The
data were mathematically analysed using the open source
software, SasView (15).
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A number of mathematical models have been explored in
this work, the one that warrants discussion here being the
unilamellar vesicle one applicable to the scattering from
DPPC based systems. In this formulism, the shape of
the vesicle is modelled as a series of concentric spheres
of varying radii (outermost corona – hydrated phospho-
lipid headgroups; middle corona – hydrocarbon region,
with thickness typically twice the length of the hydrocar-
bon tail; innermost corona - hydrated phospholipid
headgroups):
P Qð Þ ¼ ∅
V shell
3V core ρsolvent−ρshellð Þ j1 qRcoreð Þ
qRcore
þ 3V tot ρshell−ρsolventð Þ j1 qRtotð Þ
qRtot
 2
þ Binc ð4Þ
where ∅ is the volume fraction of shell material, Vshell is the
volume of the shell, Vcore is the volume of the core, Vtot is the
total volume, Rcore is the radius of the core, Rtot is the outer
radius of the shell, ρsolvent is the SLD of the solvent (similar to
the SLD of the core in this model), ρshell is the SLD of the shell
and j1 is the spherical Bessel function. In this study, scattering
from the phospholipids has been modulated by employing
tail-deuterated DPPC, which shows a significantly weakened
scattering as the hydrocarbon corona is now largely invisible
against a D2O background (16).
Statistical / Data Analysis
Non-linear regression analysis of the initial transport kinetics
of PAMAM-OG across the IPL (0–60 min) was performed
using GraphPad Prism (v5.01) according to Eq. 5 with the
recycling perfusate represented as a single accumulating com-
partment receiving first-order initial input (Kini).
M ¼ D:F 1−ekini :t  ð5Þ
Where M is the cumulative mass of probe transported
across the lung into the perfusate (0–60 min); D is the nominal
dose of PAMAM conjugate, F is the fraction of the dose de-
posited in the lung, correcting for losses in the dosing appara-
tus, Kini is the rate constant (min
−1).
For treatment comparisons results are reported ± S.D.
One-way analysis of variance (ANOVA) was used to compare
cumulative absorption data. Post-hoc analysis was performed
using Newman-Keuls Multiple comparison. Statistical signifi-
cance was determined at p < 0.05.
RESULTS
In-Vitro Transport of PAMAM and Dextran Probes
We firstly examined the transepithelial transport of anionic
PAMAM dendrimers across the Calu-3 bronchial cell line,
and compared the transport to that of a range of fluorescein-
labelled dextrans (FD) whose molecular size spanned that of the
dendrimers. Scheme 1 includes the generic molecular structure
of low generation number anionic PAMAM dendrimers, as
well as the molecular masses and the number of surface func-
tional groups of PAMAMs examined herein. Calu-3 cell mono-
layers were cultured until they reached a TEER of >500
Ω.cm2, typically around day 10–15 post-seeding. The apparent
permeability coefficients (Papp) determined from the initial lin-
ear transport rates are shown in Table I. The Papp for both
PAMAM3.5 and PAMAM5.5 were dose-independent with,
for example, the Papp for PAMAM3.5 at 40 μM and 8 μM
being respectively, 0.656 vs 0.593 (x 10−6) cm.s−1. Therefore,
over this concentration range the transport of both
PAMAM3.5 and PAMAM5.5 was predominantly one of pas-
sive diffusion. Although the Papp data for the larger molecular
sized PAMAM5.5 was consistently lower than that for the
PAMAM3.5 this was not statistical significant (p> 0.05) despite
the difference in molecular weight and molecular diameters
reported elsewhere (17). The comparative permeability profile
of Calu-3 monolayers to F-Na and a range of FDs, whose
Stokes diameters spanned 1.5 to 12 nm (Table I), was also
studied. The rate of F-Na and FD transport from a 40 μMdose
solution showed a clear inverse relationship to molecular size,
with the smallest probe, F-Na permeating most rapidly, Papp
averaging 0.737 (x 10−6) cm.s−1, whereas FD-70, the largest
solute, permeating some 30 times more slowly with an average
Papp of 0.023 (x 10
−6) cm.s−1 (Table I). Figure 1a shows such a
relationship in a plot of Papp against solute molecular diameter
for the FD panel (filled squares). The plot also overlays the
permeability data for PAMAM3.5 and PAMAM5.5 (empty
circles) whose permeabilities are clearly greater than for the
dextrans of a molecular size.
We also undertook comparative transport studies in the
Caco-2 model (Table I). As a reference the Papp to F-Na was
significantly (p < 0.05) lower for the Caco-2 monolayers com-
pared to the Calu-3 cells not withstanding TEER values
which were comparable ca. 400–500 Ω.cm2. Similarly the
permeability to PAMAM3.5 was significantly (p < 0.05) lower
in the Caco-2 cells, with the transport of PAMAM3.5 some
56% (p< 0.05) of the F-Na permeability in Caco-2, whereas in
Calu-3, the transport of PAMAM3.5 was 89% of that of the F-
Na probe (p > 0.05).
Lung Delivery of PAMAM Dendrimers
We next examined if the anionic PAMAM dendrimers
themselves could alter paracellular permeability by co-
application to the Calu-3 monolayers of unlabelled
dendrimers (each at 40 μM) together with F-Na as the
paracellular probe. Co-application of PAMAM1.5 caused
no significant change (p > 0.05) in the permeability to F-Na
(Fig. 1b), while co-application of PAMAM3.5 displayed a
trend to reduce F-Na transport although not to any significant
(P > 0.05) difference. In contrast, 40 μM PAMAM5.5 caused
a 35% reduction (p < 0.05) in the Papp of F-Na.
Endocytic Uptake and Trafficking of PAMAMs in Lung
Epithelia
Figure 2a-b demonstrate a degree of separation between the
caveolar membrane system and both the early endosomal
compartment labelled with EEA-1 (Fig. 2a, green) and the
pulse-chase dextran labelled lysosomal compartment
(Fig. 2b, green). As expected, Cav-1 puncta were widely dis-
tributed across the ATI-like cell (18). EEA-1 immunostain
(Fig. 2a) was most often identified in regions of concentrated
puncta in the peri-nuclear region, wherein a small degree of
co-localisation was observed (arrows in zoomed insert,
Fig. 2a). Similarly, in Fig. 2b it is apparent that the majority
of dextran-positive lysosomes (green) did not co-localise with
Cav-1 staining (red). To examine the functionality of these
endocytic compartments we exposed ATI-like cells to two
macromolecular probes – cholera toxin B subunit and albu-
min – both of which are used as probes of caveolae-dependent
endocytosis (19,20). ATI-like cell cultures incubated with
CtxB for 10 min (Fig. 2c) displayed a heterogeneous staining
pattern. In some cells, a 10 min internalisation period pro-
duced widespread green staining (left-hand cell, Fig. 2c) and
significant overlap between CtxB puncta and EEA-1 positive
early endosomes (arrowheads, Fig. 2c). In contrast, other cells
contained a more restricted staining intensity (e.g. right hand
cell marked with an asterix in Fig. 2c). This observation is
consistent with the heterogeneous expression of the GM1
sphingolipid receptor reported within other cell types (21).
The speckled CtxB staining pattern persisted after longer
incubation periods (arrows, Fig. 2d), however this was accom-
panied by a polarised accumulation of CtxB signal in the juxta-
nuclear region (Fig. 2d). Notably, some CtxB vesicles occupied
peripheral locations within the cell (empty arrowheads,
Fig. 2d). Co-localisation of the peri-nuclear CtxB staining to
the trans-Golgi network (TGN) using a polyclonal anti-primate
TGN-46 antibody was impossible due to poor cross-reactivity
to rat antigens. However, CtxB displayed extensive overlap
with the TGN-46 labelled compartment in A549 human
alveolar epithelial cells after 60 min internalisation (Fig. S1).
The post-Golgi trafficking of CtxB was examined following an
extended 2 h/3 h pulse-chase co-internalisation with dextran
(Fig. 2e). There was limited evidence of CtxB trafficking to
dextran-positive lysosomes in the peri-nuclear region
(arrowheads, Fig. 2e). Instead, we observed a reticular CtxB
staining pattern, which indicates the retrograde trafficking of
CtxB to the endoplasmic reticulum via the TGN (22).
After 10 min albumin (BSA) internalisation into ATI-like
cells extensive localisation of fluorescent albumin puncta
(green, Fig. 2f) to an EEA-1 positive compartment was ob-
served. In contrast to the CtxB staining pattern, albumin stain-
ing was less extensive across the cell volume and more punc-
tate in nature.
A 30 min internalisation of OG-labelled PAMAMs into
ATI-like cells resulted in a decreasing intensity of scattered
cytoplasmic puncta as PAMAM molecular size increased
(Fig. 2g-i). This was not a result of OG-labelling efficiency
between the different PAMAM species as the same labelling
stoichiometry was applied and confirmed in each case. Uptake
of the PAMAM dendrimers into cytoplasmic vesicles was
confirmed by co-localisation with endocytic marker
probes, fluorescent 10 kDa dextran (red, Fig. 2j) and
bovine serum albumin (red, Figs. 2k,l). These probes
were specifically chosen for their comparable molecular
Table I Permeability of Calu-3 and
Caco-2 Monolayers. Data Shown
are Expressed as Mean ± SD
(n = 4–6). For the 40 μM PAMAM
Concentration Data the Symbol *1
Indicates Statistical Difference
(p < 0.05) to the Permeation of All
Dextrans (FD10-FD70), While *2
Indicates Statistical Difference
(p < 0.05) to only FD 40 and
FD70. The Symbol *3 Indicates a
Significant Difference (P < 0.05) in
Permeability Between Caco-2 and
Calu-3 Monolayers for the
Respective Probe
Probe and cell line Stokes diameter (nm) Donor concentration Apparent permeability coefficient
(Papp) (x 10
−6 cm.s−1)
Calu-3
PAMAM3.5 5.2 40 μM 0.656 ± 0.102*1
PAMAM3.5 5.2 8 μM 0.593 ± 0.125
PAMAM5.5 7.9 40 μM 0.445 ± 0.154 *2
PAMAM5.5 7.9 8 μM 0.447 ± 0.098
F-Na 1.5 40 μM 0.737 ± 0.247 *1
FD10 4.6 40 μM 0.303 ± 0.087
FD20 6.6 40 μM 0.284 ± 0.089
FD40 9 40 μM 0.047 ± 0.016
FD70 12 40 μM 0.023 ± 0.011
Caco-2
F-Na 1.5 40 μM 0.345 ± 0.039 *3
PAMAM3.5 5.2 40 μM 0.194 ± 0.026 *3
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dimensions to PAMAMs 1.5, 3.5 and 5.5 and well understood
endocytic pathways. A 2 h/3 h pulse-chase co-internalisation
of PAMAM 1.5 and 10 kDa TMR-dextran (Fig. 2j) showed a
fraction of internalised dendrimer co-localised with the
dextran within peri-nuclear lysosomal compartments. A
proportion of the PAMAM 1.5 puncta remained green,
not co-localised and indicating accumulation in upstream
endocytic compartments. Co-internalisation of PAMAM
3.5 and PAMAM 5.5 with BSA (Fig. 2k and l,
respectively) resulted in both noticeable accumulation
of PAMAM puncta in the perinuclear region as well
as co-localisation with BSA positive puncta scattered
through the cell.
Transmucosal Transport of PAMAMs in the Intact Lung
The cumulative absorptive kinetics of PAMAM 1.5,
PAMAM 3.5 and PAMAM 5.5 were determined follow-
ing pMDI-mediated solution instillation into the distal
airways of the IPRL model. Figure 3a shows, as an
example, the IPRL absorptive transport profiles for
PAMAM 3.5 following either low dose (20 nmol; empty
symbols) or high dose (130 nmol; filled symbols) admin-
istration; the Figure expresses the absorption data as a
% of lung deposited dose, a parameterisation which
clearly emphasises the different kinetic outcomes.
Specifically, both the transport rate constant (Kini) and
the 60 min extent (%) of PAMAM3.5 dose absorbed
were for the low dose more than double that recorded
for the high dose (p < 0.05, Fig. 3a and Table II). Such
dose-dependent kinetics (low dose showing a faster and
greater extent of absorption compared to high dose) was
also evident for the PAMAM5.5 administration
(Table II). At near equivalent mole doses we observed
what appeared to be a distinct molecular size division in
the absorption of the dendrimer species with the extent
and rate constant of absorption for PAMAM1.5 (3.3 nm
diameter) markedly greater (P < 0.05) than both the
PAMAM3.5 (5.2 nm) and PAMAM5.5 (7.9 nm) species.
Furthermore we found the kinetics of absorption for the
latter two dendrimers species to essentially be indistin-
guishable (P > 0.05) following either the low dose com-
parison or the high dose comparison (Table II).
To provide a comparative permeability profile within
the IPRL model we also instilled a range of fluorescent-
ly labelled dextrans (FD) whose molecular weights
(3.8 kDa to 75.1 kDa) and diameters (2.8 nm to
12 nm) spanned that of the PAMAM dendrimers. For
the dextran FD20 (20.2 kDa, 6.6 nm) we tested if dose-
dependent absorption kinetics were evident across 10 to
100 nmole dose instillations. In contrast to PAMAM3.5
and 5.5 we found no evidence of a dose-dependent
absorption (P > 0.05; Table II). We also found the
same lack of dose-dependency for the small paracellular
probe, sodium fluorescein (F-Na) (Table II). Table II
also shows how the IPRL absorptive parameters for the FDs
varied as a function of size; incremental decreases in the rate
and extent of transport of the FDs within the IPRL evident
with increasing molecular weight and size. For example,
FD40 was transported x5-fold more extensively and with a
rate constant some x8-fold greater than that of FD70
(Table II). Our data are exemplified for the FDs (and F-Na)
in Fig. 3b, which also has an overlay of the equivalent data for
the PAMAMdendrimers. It is clear that PAMAMdendrimers
were somewhat more restricted in their transport than an
equivalent sized FD, which may reflect contrasting molecular
shape between the dendrimers and the dextran polymers.
Fig. 1 In-vitro transport of dendrimers and dextran probes in lung epithelial
cells (1a) Permeability of in-vitro Calu-3 cell monolayers showing a plot of Papp
(x 10−6 cm/s) as a function of Stokes diameter, and demonstrating molecular
size-dependent transport of dextrans (FD), with an overlay of F-Na perme-
ability. The permeability of the dendrimers, PAMAM3.5 and PAMAM5.5,
being considerably greater than expected based on molecular size alone;
(1b) Relative permeability of the paracellular probe F-Na and the impact of
co-incubation with unlabelled PAMAM1.5, PAMAM3.5 and PAMAM5.5. All
data n= 4–6 ± standard deviation. * denotes p< 0.05 compared to control
by one-way ANOVA and Newman-Keuls multiple comparison test.
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Here as part of the IPRL studies we sought to examine
dendrimer biocompatibility, albeit at a gross-level. We found
no acute evidence of the appearance of oedema, a qualitative
observation supported by monitoring lung wet:dry weight ra-
tios. We found no difference (P > 0.05) in lung wet:dry weight
ratios between control lungs (IPRL run for 60 min following
instillation of an equivalent dosing volume of PBS) at
4.91 ± 0.30, and OG-labelled PAMAM1.5 (4.67 ± 0.02),
PAMAM3.5 (4.78 ± 1.02) and PAMAM5.5 (4.34 ± 0.25)
dosed lungs. Monitoring paracellular permeability of the
IPRL with F-Na we observed that co-instillation of
PAMAM3.5 and F-Na caused no significant change
(p > 0.05) in the permeability to F-Na (Kini, min
−1 control
(n = 14) 0 .039 ± 0.009 v s PAMAM3.5 (n = 4)
0.043 ± 0.016). However, F-Na co-insti l led with
PAMAM5.5 led to a decrease (P< 0.05) in the permeability
to F-Na (Kinimin
−1 control (n= 14) 0.039 ± 0.009 vs PAMAM
5.5 (n = 4) 0.018 ± 0.002).
SANS Investigations of PAMAM-Macromolecule
Interactions
We next employed small angle neutron scattering (SANS) to
investigate the molecular structure of PAMAMs in binary and
tertiary models of lung lining fluid. To establish baseline data
wemodelled the SANS fromBSA and PAMAM3.5 and 5.5 in
deuterated water (Fig. 4a). The models determined the mo-
lecular radii (RG) for BSA, PAMAM 3.5 and PAMAM 5.5 of
28, 20 and 30 Å, respectively. These PAMAMdimensions are
consistent with hydrodynamic radii data determined by others
using diffusion NMR (17). The use of deuterated DPPC (d-
DPPC) in D2O reduces the normally high scattering intensity
of hydrogen-containing lipids (h-DPPC) in D2O. This
Bcontrast^ approach was used to determine that the DPPC
SUVs displayed radii of 580 Å with a bilayer thickness of 30–
40 Å (Fig. 4b, Table III). When we made binary mixtures of
DPPCwith BSA (Fig. 4c) or with PAMAM 3.5 or 5.5 (Fig. 4d)
Fig. 2 Distribution and
functionality of endocytic
compartments in ATI-like lung
epithelia. Co-localisation of
Caveolin-1 positive vesicles with
(2a) EEA-1 immunopositive
endosomes and (2b) lysosomes
labelled by a 2 h/3 h pulse-chase
internalization of dextran. CtxB
internalized into ATI-like cells
localizes to (2c) early endosomes
after 10 min, (2d) a peri-nuclear
compartment after 45 min. (2e)
only a minor fraction of CtxB puncta
localized to lysosomes following a
2 h/3 h pulse-chase co-
internalisation of CtxB and 10 kDa
dextran. Empty arrowheads in 2D
highlight non-perinuclear puncta
present within upstream
compartments. (2f) TMR-labelled
BSA accumulated in EEA-1 positive
endosomes after a 10 min
incubation. (2g–I) Primary ATI-like
cells show a decrease in the density
of PAMAM-OG staining density
pattern that accompanies an
increase in dendrimer generation
from 1.5 to 5.5 after 30 min
incubation. (j) a fraction of PAMAM
1.5 co-localised with dextran
labelled lysosomes after a 2 h/3 h
pulse-chase co-internalisation. Both
PAMAM 3.5 (k) and PAMAM 5.5 (l)
co-localise with BSA after 30 mins
co-internalisation. Arrows in
zoomed section highlight co-
localised puncta. Scale bar: 5 μm.
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we found the scattering intensities of binary mixtures were
equal to the sum of their components parts, thus indicating
no significant interaction between the paired components.
Similarly, the scattering intensities of ternary solutions (lipid,
PAMAM, protein, Fig. 4e, Table III) were equivalent to spec-
tra predicted by simple addition of scattering intensities from
the individual components.
DISCUSSION
In this work we sought to provide a detailed examination of
the pulmonary disposition of anionic PAMAM dendrimers
using a combination of in vitro cell cultures and intact
ex vivo IPRL model. Transport experiments using restrictive,
polarised Calu-3 monolayers demonstrated that PAMAM3.5
Fig. 3 Pulmonary transport of anionic PAMAM dendrimers
across the IPRL. (a) Example cumulative transport profile for the airway
to perfusate absorption of PAMAM 3.5 following instillation of 20 nmol (empty
circles) or 130 nmol (filled circles); (b) shows the relationship between solute
Stokes diameter and the kini rate constant for PAMAM dendrimers (empty
circles) and FD or F-Na (filled squares). Two empty symbols are shown in
panel B when two different PAMAM dose levels were tested. Data shown are
mean ± SD, n = 3–4.
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Fig. 4 SANS as a function of (a) PAMAMs/BSA, (b) h and d-DPPC, (c) mixtures of h-DPPC/BSA and d-DPPC/BSA, (d) mixtures of h-DPPC/PAMAMG3.5 and
h-DPPC/PAMAM G5.5, (e) mixtures of 10 mM d-DPPC/4 mg.ml-1 BSA/1.3 mM PAMAM G3.5 and 10 mM d-DPPC/4 mg.ml-1 BSA/1.3 mM PAMAM G5.5.
Solid lines corresponds to the model fits as discussed in the text. Data has been offset for clarity.
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and PAMAM5.5 permeate these monolayers at rates higher
than control solutes (FITC-dextrans) of comparablemolecular
dimensions. Unexpectedly, the permeability to F-Na de-
creased when co-applied with PAMAM 5.5. That the mono-
layer TEER remained stable throughout the studies leads us
to interpret this apparent reduced F-Na permeability to reflect
a degree of sequestration of F-Na by the dendrimer, and
hence a reduced F-Na concentration available for free trans-
port. Nevertheless, together the data supported the conclusion
that tight junctional modulation is not a key factor in anionic
PAMAM transport across Calu-3.
The interaction between PAMAM dendrimers and epithe-
lial tight junctional proteins has been investigated by a num-
ber of groups, principally using the Caco-2 cell model. Avaritt
and Swann reported the anionic PAMAM3.5 to lead to a
concentration-dependent increase in immunofluorescence
staining intensity for tight junction-associated proteins, al-
though this was not associated with an increased protein ex-
pression or altered functional paracellular permeability. In
contrast, the cationic PAMAM G4 resulted in significant in-
creases in paracellular permeability through a mechanism(s)
mediated via intracellular Ca2+ release. Two previous studies
have reported PAMAM3.5 transport across Caco-2 cells, both
studies applying very high dendrimer concentrations
(1000 μM) and with markedly different permeability out-
comes, i.e. Jevprasanephant et al. (23) reporting a Papp of
0.02 (x10−6) cm.s−1 while Kitchens et al. (24) reported a 300-
fold higher Papp of 6 (x10
−6) cm.s−1. Nevertheless, this rein-
forces the disconnection that can be apparent between differ-
ent in-vitro cellular barrier modelss, the TEER measurements
and the permeability of paracellular probes and the transport
of experimental agents such the dendrimers; a disconnection
that supports studies in a more physiologic lung model that
reflects the epithelial barriers of the deep lung.
A number of published reports have concluded that
endocytic uptake and / or transcytosis across epithelial bar-
riers could play a significant role in the net transmucosal
dendrimer transport (6,25). We next gathered spatiotemporal
information on the expression and functionality of macromo-
lecular uptake pathways to examine their role in dendrimer
uptake by lung alveolar cells. A combination of fixed cell
immunolabelling and live cell imaging of primary rat ATI-
like cells confirmed limited co-localisation of intracellular pop-
ulations of Cav-1 positive, EEA-1 positive and dextran-loaded
lysosomes. Spatial segregation is a key feature of polarised
epithelial cells such as lung alveolar epithelia because it affords
proper control of many key processes including, but not lim-
ited to, cell adhesion, migration and nutrient uptake (26).
Each of these distinct endocytic compartments was shown to
fulfil a functional role in the uptake of probes with molecular
dimensions comparable to the size range of PAMAM
dendrimers (3.3–7.9 nm) that were studied here i.e. 10 kDa
dextran (4.6 nm), CtxB (6.5 nm (27)) and albumin (6.8 nm
(28)). Co-localisation of internalised dendrimer with
immunolabelled compartments was not performed due to
fixation-associated artefacts that can misrepresent polymer
uptake patterns.
CtxB binds to GM1 ganglioside within ordered microdo-
mains termed lipid rafts and the toxin B subunit specifically
serves to deliver the catalytic A subunit of the holotoxin to the
endoplasmic reticulum and subsequently to the cytosol (29).
Demonstrable uptake and trafficking of CtxB within primary
rat alveolar epithelia indicates Cav-1 functionality in the pul-
monary epithelial barrier. To complement this, BSA was used
as a probe for non-specific fluid-phase endocytosis as it results
in considerably less background fluorescence on the glass cov-
erslips after short incubation periods compared to, for exam-
ple dextrans. This can be particularly challenging when imag-
ing ATI-like cells due to the highly attenuated cell periphery
(30). The internalisation of albumin has been linked to the
gp60 (albondin) receptor-mediated uptake of proteins in lung
alveolar epithelial cells (31) although this has not been widely
confirmed.
Lung ATI cells represent 95% of the lung absorptive sur-
face area and express caveolin-1 (Cav-1) as a phenotypic bio-
chemical marker. Cav-1 (32,33) and macromolecular traffick-
ing via caveolae has been targeted for enhanced delivery of
nanoparticles and macromolecules (34). A detailed investiga-
tion of the trafficking mechanisms of PAMAMs in lung epi-
thelia was beyond the scope of this study. Nonetheless, these
data provide a novel insight into the endocytic capacity of ATI
cells and lead us to conclude that the endocytic machinery of
alveolar epithelia, including Cav-1 positive vesicles (35,36),
fulfil a role in the uptake and intracellular trafficking of mac-
romolecules such as PAMAM dendrimers at the air-blood
barrier, as described previously (37) for other cellular barriers.
The contribution of endocytic/transcytotic mechanisms to the
bulk transport of polymers across epithelial barriers is ex-
tremely challenging to deconvolute. The use of chemical
and/or genetic knockdown techniques inevitably leads to the
Table III Structural Key Parameters of 10mM h-DPPC / d-DPPCObtained
from the SANSModel Fitting as a Function of PAMAMs or BSAConcentration at
25°C in D2O. ND: Not Determinable Due to Low Contrast
Sample description Vesicle radius
(± 10, Å)
Vesicle bilayer
thickness (± 5, Å)
h-DPPC 580 38
h-DPPC +1.3 mM PAMAM G3.5 580 35
h-DPPC +1.3 mM PAMAM G5.5 570 35
h-DPPC +2 mg.ml−1 BSA 580 40
d-DPPC ND 30
d-DPPC +4 mg.ml−1 BSA 580 50
d-DPPC +1.3 mM PAMAM G3.5
and 4 mg.ml−1 BSA
580 35
d-DPPC +1.3 mM PAMAM G5.5
and 4 mg.ml−1 BSA
580 50
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modulation of the paracellular transport route, which is most
likely the predominant transport pathway for unmodified
polymeric carriers displaying sub-10 nm dimensions.
We next employed the IPRL model to s tudy
transpulmonary PAMAM transport. This model gives insight
into the complex parallel dispositional barriers to absorption
from the airways within an intact lung architecture without
the confounding whole body distribution and elimination pro-
cesses such as mucociliary clearance (MCC). The absorption
kinetics of PAMAMs and control FD probes displayed a re-
ciprocal dependency between transport and solute size, con-
sistent with a restricted diffusional process. More importantly,
anionic PAMAMdendrimers displayedmodest lung transport
kinetics cf. similarly sized FD solutes. We have previously
demonstrated (38,39), using a range of small molecule probes,
that the IPRL model discriminates between rapidly absorbed
lipophilic compounds such as digoxin (absorption t1/2, 6 min)
from polar, paracellular probes such as mannitol (absorption
t1/2, 63 min). The range of absorption half-lives recorded for
PAMAMs here spanned 100–600 min, illustrating the
prolonged transpulmonary absorption cf. smaller solutes. A
rate of polymer clearance from the lung airways that is in-
versely proportional to molecular weight is, of course, not
unique, with comparatively recent studies reporting similar
profiles with polylysine dendrimers (40), polyethylene glycol
polymers (0.5 to 20 kDa) (41) and hyaluronic acid polymers (7
to 741 kDa) (42). In the case of dendrimer administration to
the lung Ryan et al. (40) recently reported a relative lung bio-
availability of 20–30% for pegylated polylysine dendrimers in
the range of 11-22 kDa (3.0–5.7 nm) after in vivo intratracheal
instillation. da Rocha and colleagues (43,44) administered to
miceG3 PAMAMand its pegylated derivatives by pharyngeal
aspiration and reported absorption kinetics that were signifi-
cantly faster than those reported here i.e. absorption half-lives
in the range of 120 min. Direct comparison of our data with
others is precluded by contrasting approaches such as the use
of different PAMAM types, deposition in the central lung
in vivo cf. peripheral lung ex vivo, as well as dispositional dis-
parities, including the presence of mucociliary clearance
in vivo, which permits a contribution to bioavailability by gas-
trointestinal absorption. It should be highlighted that the tra-
cheobronchial circulation is not perfused in the IPRL model
and the forced solution instillation delivers >90% of the
instilled dose into the peripheral lung regions, with the re-
maining fraction largely confined to the dosing apparatus
(10). In combination, these two key features of our IPRLmod-
el allow us to interpret the appearance of solutes in the
recirculating pulmonary perfusate as a direct consequence of
absorption across the deep lung epithelium, with negligible
impact of MCC. In contrast to other earlier works in other
mucosal models (45) our data indicate that deep lung delivery
of anionic PAMAMs is unlikely to enhance drug absorption
kinetics. Hubbard et al. (46) concluded that PAMAMs exhibit
only modest transepithelial transport across intact human in-
testinal epithelial sheets and that, similar to our results, trans-
port rate is overestimated by in vitro (Caco-2) monolayers.We
would therefore advise that caution should be exercised when
interpreting only in vitro permeability profiles of dendrimeric
carriers for lung delivery. Our observation does not exclude
the opportunity to exploit PAMAMs for controlled release of
low molecular weight drugs into or across the lung epithelia as
previously demonstrated with PEG polymers (47).
The biocompatibility of inhalation delivery platforms is a
critical consideration in the future development of
nanomedicines. The decreased permeability observed in both
Calu-3 and IPRL studies indicates that PAMAM 5.5 reduces
the concentration of diffusible F-Na at the epithelial surface.
Bonizzoni et al. (48) recently showed that cationic PAMAM
dendrimers reversibly interact with, and induce aggregation
of, the structurally related fluorescein dye, 5,6-carboxyfluores-
cein leading to dye sequestration. Anionic dendrimers would
not be expected to drive such an exact binding event. More
likely could be the interaction between fluorescein and the sec-
ondary and tertiary amine groups within the dendrimer core.
The capacity for lung-instilled solutes to cause epithelial
barrier disruption was reported previously. Intra-tracheal in-
stillation of cationic PAMAM G3 has been associated with
acute lung injury (49). Similarly, we recently showed that in-
stillation of select cationic, amphipathic peptides into the
IPRL causes dose-dependent increases in the permeability to
mannitol (12). Our data complement a number of in vitro
cytotoxicity studies (50,51) which conclude that anionic
PAMAMs offer greatly reduced potential to cause cellular
damage compared to cationic dendrimers.
We reported above that at higher doses both the
PAMAM3.5 and 5.5 species showed a reduced transport rate
constant (Kini) and extent (%) of absorption within the IPRL.
Intriguingly, transport of the similarly sized FD20 polymer
was identical across a 10-fold dose range, indicating that
dose-dependent phenomenon for PAMAM3.5 and 5.5 is not
a generalised issue within the IPRLmodel but rather a feature
of the PAMAM polymer species. A technical point is that size
exclusion chromatography performed as previously described
(10) upon all labelled PAMAM and FD dosing solutions and
upon the respective 60 min IPRL perfusate samples (data not
shown), confirmed the integrity of all fluorescent conjugates
and as such the validity of the kinetic transport interpretation.
We wondered if dose-dependent PAMAM transport may be
due to PAMAM aggregation within the lung lining fluids.
Using SANS analysis of PAMAMs in a relatively simple model
of the lung lining fluid we observed that PAMAM generations
3.5 and 5.5 do not aggregate or adsorb to DPPC vesicles. The
20Å increase in the bilayer thickness of d-DPPC vesicles in the
presence of 4 mg/ml BSA or PAMAMG5.5 + 4 mg/ml BSA
is not interpretable as a binding or membrane insertion. Using
the simplest conceptual model of albumin or PAMAM
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binding with DPPC vesicles, we predict that the average
DPPC vesicle radii would increase by at least one BSA/
PAMAM molecular diameter (40–60 Å). The pulmonary
(alveolar) epithelial surface is covered with surfactant com-
posed predominantly of lipid (90%) and with the remainder
protein. Dipalmitoylphosphatidylcholine (DPPC) is the major
lipid component, comprising 30–60% of the total lipid surfac-
tant content (52). Interactions between PAMAM dendrimers
andmodel lipid membranes have been previously investigated
using a range of biophysical methods to examine membrane
interaction and cytotoxicity (53–55). The majority of pub-
lished studies on dendrimer-membrane interactions have fo-
cussed upon cationic PAMAM dendrimers. However, of par-
ticular relevance to our data Lombardo et al. (56) recently
observed DPPC alkyl chain disruption by PAMAM2.5, which
was mirrored by increases in vesicle zeta potential and mod-
ulated SAXS spectra. The technique of co-dissolution of
PAMAMs with DPPC prior to liposome extrusion, as used
by Lombardo et al., is likely to increase the probability of
intermolecular interactions between the components and the
entrapment of dendrimer within the interfacial lipid region.
This is highly unlikely in our system when PAMAM were
mixed with colloidally stable DPPC vesicles. Here we have
excluded PAMAM aggregation with DPPC or albumin fluid
components. The possibility remains that PAMAM aggrega-
tion or sequestration with other lung luminal components, e.g.
complex formation with innate cell membranes (57), innate
defence proteins, other serum proteins or surfactant proteins,
could explain the dose-dependent transport kinetics.
CONCLUSION
Transport of PAMAM 3.5 and 5.5 across in-vitro Calu-3
monolayers was faster than predicted by solutes of compara-
ble molecular dimensions but slower than that reported by
others in different epithelial monolayer systems e.g. intestinal
models. The expression and functionality of endocytic uptake
pathways, including caveolae, in primary alveolar epithelial
cells were confirmed for the uptake of PAMAM dendrimers
as well as model macromolecular probes. In an ex-vivo IPRL
model dendrimers did not compromise epithelial barrier in-
tegrity, although the airway-to-blood transport kinetics were
dose-dependent and restricted compared to solutes of compa-
rable size. Neutron scattering experiments confirmed that
PAMAMs do not aggregate in a model lung lining fluid
supporting the conclusion that PAMAM self-association is un-
likely to be a significant factor in the pulmonary disposition of
dendrimer carriers. In summary, anionic PAMAM
dendrimers have a favourable lung biocompatibility profile,
display rapid uptake into respiratory epithelia and prolonged
lung transport kinetics. These findings strongly support the
future development of inhaled PAMAM-based drug delivery
systems for modified local drug delivery to lung epithelia as
well as transpulmonary drug delivery.
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